Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) ELISA Kits

CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C19 Antibodies (39) and CYP2C19 Proteins (3) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
CYP2C19 1557 P33261
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top CYP2C19 ELISA Kits at

Showing 3 out of 19 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Rat 0.28 ng/mL 0.78-50 ng/mL 96 Tests Log in to see 13 to 16 Days
Human 0.264 ng/mL 0.62 ng/mL - 40 ng/mL 96 Tests Log in to see 13 to 16 Days
Human 0056 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests Log in to see 15 to 17 Days

More ELISA Kits for CYP2C19 Interaction Partners

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) interaction partners

  1. CYP2C19 genotype-based dosing combined with therapeutic drug monitoring will support individualization of Voriconazole dosing, and potentially will minimize toxicity and maximize therapeutic efficacy

  2. The combined genotype of CYP3A5*1/*3 and CYP2C19*1/*1 was associated with a low level of VASP phosphorylation, while either genotype was not. A multivariate analysis showed that high residual platelet reactivity during the cilostazol treatment, which was defined by a low response of platelet VASP phosphorylation to cilostazol, was an independent risk factor for the recurrence of thrombotic events.

  3. Minor allele frequencies (MAF) in a Puerto Rican population were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in HardyWeinberg equilibrium (HWE).

  4. The frequency distribution of alleles CYP2C19 in Yakuts is between that in the representatives of Mongoloid and Caucasian races, which can be explained by the history of forming the population of this particular region.

  5. The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes.

  6. CYP2C19*2 genotype-guided antiplatelet treatment remained a cost-effective strategy.

  7. CYP2C19 SNP was significantly associated with high on-treatment platelet reactivity and clinical outcomes after percutaneous coronary intervention.

  8. Polymorphisms of the CYP2C19 is associated with Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-Hematopoietic Stem Cell Transplantation.

  9. In a subject with predicted CYP2C19 PM phenotype, the PK of BMS-823778 was affected significantly by UGT1A4 polymorphism.

  10. Wild-type CYP2C19*1B and 30 isoforms were highly expressed in insect cells, and the enzymatic activities of CYP2C19 variants towards nebivolol hydroxylation were characterized. Three variants, CYP2C19*29 (K28I), L16F, and CYP2C19*23 (G91R), showed increased intrinsic clearance of >140% CYP2C19*1B.

  11. Carriage of a combination of mutant alleles in multiple genes including ITGB3+CYP2C19*2 or CYP2C19*2 + ITGA2 or CYP2C19*2 are possible predictors of CVE in patients after CABG

  12. Gene polymorphism testing results indicated that patients with CYP2C19*3 had a significantly higher incidence of high on-treatment platelet reactivity.

  13. CYP2C19 genotype only partially determines the CYP2C19 phenotypic appearance.

  14. appears that 5azaDC treatment affects an unidentified upstream regulator of both CYP2C19 and/or NR1I3. This is supported by the fact that the relationships between TF for CYP2C19 and the expression of this target gene in human liver samples only accounted for approximately 70% of the variability of CYP2C19 mRNA levels.

  15. For percutaneous coronary intervention in postoperative patients, research data is still lacking regarding clopidogrel dosage on the basis of different CYP2C19 genotypes.

  16. Even heterozygous CYP2C19*2 allele carriers among Caucasian patients after ischemic stroke had a higher risk of major adverse clinical events.

  17. results obtained from this study have proven the CYP variants to be immunoreactive and spectrally active and are suitable for use to examine biotransformation and interaction mechanism of the enzymes

  18. Report association of CYP2C19 genotype with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

  19. Personalized treatment with clopidogrel or ticagrelor based on CYP2C19 genotype status ultimately led to improved clinical outcomes in acute coronary syndrome patients treated with percutaneous coronary intervention.

  20. CYP2C19*2 Polymorphism is associated with drug resistance in Breast Cancer.

CYP2C19 Antigen Profile

Antigen Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C19

  • cytochrome P450 family 2 subfamily C member 19 (CYP2C19) antibody
  • cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) antibody
  • cytochrome P450 2C19 (CYP2C19) antibody
  • CPCJ antibody
  • CYP2C antibody
  • P450C2C antibody
  • P450IIC19 antibody

Protein level used designations for CYP2C19

(R)-limonene 6-monooxygenase , (S)-limonene 6-monooxygenase , (S)-limonene 7-monooxygenase , CYPIIC17 , CYPIIC19 , S-mephenytoin 4-hydroxylase , cytochrome P-450 II C , cytochrome P450 2C19 , cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 , cytochrome P450-11A , cytochrome P450-254C , flavoprotein-linked monooxygenase , mephenytoin 4'-hydroxylase , mephenytoin 4-hydroxylase , microsomal monooxygenase , xenobiotic monooxygenase , cytochrome P450 2C

1557 Homo sapiens
510380 Bos taurus
100534653 Ovis aries
Selected quality suppliers for CYP2C19 (CYP2C19) ELISA Kits
Did you look for something else?